174 related articles for article (PubMed ID: 16283539)
1. Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development.
Stanski DR; Rowland M; Sheiner LB
J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):199-211. PubMed ID: 16283539
[TBL] [Abstract][Full Text] [Related]
2. Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development.
Krishna R; Schaefer HG; Bjerrum OJ
Eur J Pharm Sci; 2007 May; 31(1):62-7. PubMed ID: 17408933
[TBL] [Abstract][Full Text] [Related]
3. Network on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences.
Mochel JP; Tyden E; Hellmann K; Vendrig JC; Şenel S; Dencker L; Cristina RT; Linden H; Schmerold I
J Vet Pharmacol Ther; 2018 Jun; 41(3):378-383. PubMed ID: 29266320
[TBL] [Abstract][Full Text] [Related]
4. Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report.
Burgess DJ; Crommelin DJ; Hussain AS; Chen ML;
AAPS PharmSci; 2004 Mar; 6(1):E11. PubMed ID: 15198512
[TBL] [Abstract][Full Text] [Related]
5. Integrating systems approaches into pharmaceutical sciences.
Westerhoff HV; Mosekilde E; Noe CR; Clemensen AM
Eur J Pharm Sci; 2008 Sep; 35(1-2):1-4. PubMed ID: 18602464
[TBL] [Abstract][Full Text] [Related]
6. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development.
Rolan P; Atkinson AJ; Lesko LJ; ;
Clin Pharmacol Ther; 2003 Apr; 73(4):284-91. PubMed ID: 12709718
[No Abstract] [Full Text] [Related]
7. The Global Bioequivalence Harmonization Initiative: Summary report for EUFEPS international conference.
Chen ML; Blume H; Beuerle G; Davit B; Mehta M; Potthast H; Schug B; Tsang YC; Wedemeyer RS; Weitschies W; Welink J
Eur J Pharm Sci; 2018 Jan; 111():153-157. PubMed ID: 28964950
[TBL] [Abstract][Full Text] [Related]
8. An assessment of future training needs for PhD graduates for European pharmaceutical companies: a report from the committee on industrial relations (CIR) of EUFEPS. European Federation for Pharmaceutical Sciences.
Eur J Pharm Sci; 1999 Feb; 7(3):iii-v. PubMed ID: 10048939
[No Abstract] [Full Text] [Related]
9. Pharmaceutical Portfolio & Product Life Cycle Management--SMi's fourth annual conference. 29-30 June 2009, London, UK.
Beecher N
IDrugs; 2009 Sep; 12(9):558-60. PubMed ID: 19697274
[No Abstract] [Full Text] [Related]
10. EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. European Federation of Pharmaceutical Sciences.
Tucker GT; Houston JB; Huang SM
Eur J Pharm Sci; 2001 Jul; 13(4):417-28. PubMed ID: 11480400
[No Abstract] [Full Text] [Related]
11. [The Innovative Medicine Initiative (IMI)].
Bril A; Canet E
Med Sci (Paris); 2008 Oct; 24(10):885-90. PubMed ID: 18950588
[TBL] [Abstract][Full Text] [Related]
12. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
[TBL] [Abstract][Full Text] [Related]
13. [Are children getting the right drugs?].
Bratlid D
Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857
[TBL] [Abstract][Full Text] [Related]
14. The global bioequivalence harmonisation initiative: Report of EUFEPS/AAPS third conference.
Mehta M; Blume H; Beuerle G; Tampal N; Schug B; Potthast H; Jiang W; Wilson C
Eur J Pharm Sci; 2020 Aug; 151():105383. PubMed ID: 32473200
[TBL] [Abstract][Full Text] [Related]
15. "Getting the dose right": facts, a blueprint, and encouragements.
Peck CC; Cross JT
Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
[No Abstract] [Full Text] [Related]
16. Evaluation and recommendations on adaptive dose-ranging trials: highlights from the PhRMA Adaptive Dose-Ranging Studies Working Group.
Pinheiro J
J Clin Pharmacol; 2010 Sep; 50(9 Suppl):47S-49S. PubMed ID: 20881216
[No Abstract] [Full Text] [Related]
17. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.
Robinson S; Delongeas JL; Donald E; Dreher D; Festag M; Kervyn S; Lampo A; Nahas K; Nogues V; Ockert D; Quinn K; Old S; Pickersgill N; Somers K; Stark C; Stei P; Waterson L; Chapman K
Regul Toxicol Pharmacol; 2008 Apr; 50(3):345-52. PubMed ID: 18295384
[TBL] [Abstract][Full Text] [Related]
18. Second-Generation Pharmaceutical Proteins-EUFEPS Workshop on Optimizing Biotech Medicines.
Pasut G; Veronese FM
IDrugs; 2007 Mar; 10(3):162-4. PubMed ID: 17351866
[No Abstract] [Full Text] [Related]
19. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
Milton MN; Horvath CJ
Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
[No Abstract] [Full Text] [Related]
20. European drug industry concerned over proposed clinical-trial legislation.
Rogers A
Lancet; 1997 Nov; 350(9091):1609. PubMed ID: 11655209
[No Abstract] [Full Text] [Related]
[Next] [New Search]
